ImmunityBio (STU:26CA) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:26CA ImmunityBio Inc STU:26CA
64 GF Score
Price €7.25
GF Value €19.60
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ImmunityBio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:26CA vs RYTM, PCVX, MIRM: Short Interest Comparison

For the Biotechnology subindustry, ImmunityBio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunityBio Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's Short Interest distribution charts can be found below:

* The bar in red indicates where ImmunityBio's Short Interest falls into.


STU:26CA
64GF Score
ImmunityBio Inc STU:26CA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ImmunityBio (STU:26CA) Overvalued in 2026?

Based on GuruFocus' analysis, ImmunityBio stock appears to be undervalued. The current stock price of €7.25 is trading 63% below its estimated GF Value™ of €19.60. GuruFocus considers ImmunityBio to be Possible Value Trap.

Key valuation signals for STU:26CA:

  • Short Interest:
  • GF Value™: €19.60 vs. price of €7.25 (63% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the STU:26CA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmunityBio Business Description

Other Exchanges IBRX:USA
Address 3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
64GF Score

Get the complete analysis for STU:26CA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.25
Price
€19.60
GF Value